• Profile
Close

Comparison of efficacy and safety of liraglutide 3.0 mg in individuals with BMI above and below 35 kg/m²: A post-hoc analysis

Obesity Facts Nov 20, 2017

le Roux C, et al. - This post-hoc analysis was performed to examine whether the efficacy and safety of liraglutide 3.0 mg differed between 2 subgroups (BMI 27 to <35 and BMI ≥ 35 kg/m²) in individuals without and with type 2 diabetes (T2D). The researchers found no differences in the treatment effects, or safety profile, of liraglutide 3.0 mg for individuals with BMI 27 to <35 or ≥35 kg/m². Thus, liraglutide 3.0 mg could be considered for individuals with a BMI of ≥35 as well as for those with a BMI of 27 to <35 kg/m².
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay